Pregnancy Registries Are Insufficient To Assess Drug Safety, US FDA Says
Executive Summary
Draft guidance recommends complementary studies to evaluate effects of drug use during pregnancy; FDA may require lactation studies more frequently.
You may also be interested in...
EMA Aims For Better Info On Benefit-Risk Balance To Support Drug Choices In Pregnancy
The European Medicines Agency is developing a strategy to ensure that women have sufficient information to make informed choices about taking medicines during pregnancy and breastfeeding.
US FDA’s Higher Bar For Postmarketing Pregnancy Studies Shown By AMAG’s Vyleesi, Sprout’s Addyi
Agency’s postmarketing requirements to assess Vyleesi risk in pregnant and lactating women highlight the changes catalyzed by draft guidances issued in April.
Beyond Pregnancy Registries: Complementary Post-Marketing Approaches
New techniques cannot replace registries but can address their limitations, stakeholders tell FDA.